Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Epigenetics in Drug Discovery

Sophie Postel-Vinay's Biography



Sophie Postel-Vinay, Group Leader, Institut Gustave Roussy

Sophie Postel-Vinay (MD, Ph.D), is currently Physician Scientist at the Drug Development Department and U981 INSERM research unit of Gustave Roussy Cancer Campus. She received her medical degree from the Université René Descartes Paris V in 2010, and joined the faculty in November 2013 after completion of her PhD. She completed her residency training in Paris (Institut Gustave Roussy and Assistance Publique Hôpitaux de Paris), and spent 18 months at the Royal Marsden Hospital of London in Pr Stan Kaye and Dr De Bono Drug Development Unit. Dr Postel-Vinay is member of AACR and ASCO, from which she received a merit award in 2010. She is also an ESMO member, former representative of the French Young Oncologist at the Young Oncologists Committee, and received the ESMO translational research fellowship for her PhD that was performed at the Institute of Cancer Research (London). Dr Postel-Vinay is also working in the INSERM Unit 981, where she is studying chromatin remodeling and its interplay with DNA repair defects and immune modulation in lung cancer models. Her research interests include epigenetics, DNA repair and synthetic lethality, predictive biomarkers, drug development and emerging targets.

Sophie Postel-Vinay Image

Mechanism-Based Therapeutic Targeting Of Epigenetic Abnormalities In Solid Tumours: Clinical Update And Future Directions

Monday, 6 March 2017 at 11:15

Add to Calendar ▼2017-03-06 11:15:002017-03-06 12:15:00Europe/LondonMechanism-Based Therapeutic Targeting Of Epigenetic Abnormalities In Solid Tumours: Clinical Update And Future DirectionsSELECTBIOenquiries@selectbiosciences.com

This talk will provide key notions about targeting defects in chromatin remodeling using synthetic lethality or epigenetic antagonism, with the results of two clinical trials in which our unit was involved as an illustration. The rationale for using combinatorial approaches, notably with immune therapies, will also be discussed based on current available literature data.


Add to Calendar ▼2017-03-06 00:00:002017-03-07 00:00:00Europe/LondonEpigenetics in Drug DiscoverySELECTBIOenquiries@selectbiosciences.com